Pojo et al. also demonstrated in vivo and in vitro that HOXA9 can upregulate Bcl-2 and lead to the temozolomide treatment resistance of patients with glioma, providing a new idea for the treatment of glioma [37]. Here, BCL2 is linked to central nervous system cancer.